Andres J. Pumariega, Amor S. Del Mundo, and Booney Vance
- Published in print:
- 2002
- Published Online:
- January 2009
- ISBN:
- 9780195134575
- eISBN:
- 9780199864065
- Item type:
- chapter
- Publisher:
- Oxford University Press
- DOI:
- 10.1093/acprof:oso/9780195134575.003.0012
- Subject:
- Social Work, Health and Mental Health, Communities and Organizations
This chapter discusses psychopharmacological treatment for children's emotional and psychiatric disorders. It considers approaches to the selection of pharmacological agents. It then reviews the ...
More
This chapter discusses psychopharmacological treatment for children's emotional and psychiatric disorders. It considers approaches to the selection of pharmacological agents. It then reviews the current state of psychopharmacological treatment with children and adolescents, focusing on pharmacological agents for the treatment of established psychiatric diagnoses and psychopharmacological agents selected to control or treat behaviors experienced by the child regardless of the presence of a clear diagnosis.Less
This chapter discusses psychopharmacological treatment for children's emotional and psychiatric disorders. It considers approaches to the selection of pharmacological agents. It then reviews the current state of psychopharmacological treatment with children and adolescents, focusing on pharmacological agents for the treatment of established psychiatric diagnoses and psychopharmacological agents selected to control or treat behaviors experienced by the child regardless of the presence of a clear diagnosis.
D. E. JANE, H. J. OLVERMAN, and J. C. WATKINS
- Published in print:
- 1995
- Published Online:
- March 2012
- ISBN:
- 9780192625021
- eISBN:
- 9780191724701
- Item type:
- chapter
- Publisher:
- Oxford University Press
- DOI:
- 10.1093/acprof:oso/9780192625021.003.0002
- Subject:
- Neuroscience, Molecular and Cellular Systems
A wealth of information has now been generated, especially from radioligand binding studies, regarding the structural requirements for agonist and antagonist binding to the glutamate recognition site ...
More
A wealth of information has now been generated, especially from radioligand binding studies, regarding the structural requirements for agonist and antagonist binding to the glutamate recognition site on the NMDA receptor. In combination with a number of molecular modelling studies this has been used to elucidate the three-dimensional topology of the receptor site and thus provide a basis for a rational design of new pharmacological agents with agonist or antagonist action at these sites. This chapter outlines the required structural features for agonist and antagonist binding. It then discusses the various molecular modelling studies which have recently been carried out.Less
A wealth of information has now been generated, especially from radioligand binding studies, regarding the structural requirements for agonist and antagonist binding to the glutamate recognition site on the NMDA receptor. In combination with a number of molecular modelling studies this has been used to elucidate the three-dimensional topology of the receptor site and thus provide a basis for a rational design of new pharmacological agents with agonist or antagonist action at these sites. This chapter outlines the required structural features for agonist and antagonist binding. It then discusses the various molecular modelling studies which have recently been carried out.
- Published in print:
- 2007
- Published Online:
- March 2013
- ISBN:
- 9780226500768
- eISBN:
- 9780226500935
- Item type:
- chapter
- Publisher:
- University of Chicago Press
- DOI:
- 10.7208/chicago/9780226500935.003.0010
- Subject:
- History, Cultural History
On March 27, 1998, Viagra became the first oral medication to be approved by the U.S. Food and Drug Administration to treat erectile dysfunction. A flood of books and articles, which shows no sign of ...
More
On March 27, 1998, Viagra became the first oral medication to be approved by the U.S. Food and Drug Administration to treat erectile dysfunction. A flood of books and articles, which shows no sign of abating, has subsequently been devoted to analyzing the pill's impact. Among the more insightful is Meika Loe's The Rise of Viagra: How the Little Blue Pill Changed Sex in America (2004). But what does it mean to say sex is changed? Is Viagra a wonder drug? A magic bullet? The rejuvenating potion doctors sought for centuries? Supporters of the medicalization of sexuality certainly claim as much. Previous surveys suggested that when strictly defined as the inability to get an erection perhaps ten percent of men suffered at times from impotence. To appreciate the Viagra phenomenon we need to trace the emergence of the new pharmacological agents that arose in the 1990s but then situate them in the context of changing cultural attitudes toward masculinity, medicine, and the enhancement technologies.Less
On March 27, 1998, Viagra became the first oral medication to be approved by the U.S. Food and Drug Administration to treat erectile dysfunction. A flood of books and articles, which shows no sign of abating, has subsequently been devoted to analyzing the pill's impact. Among the more insightful is Meika Loe's The Rise of Viagra: How the Little Blue Pill Changed Sex in America (2004). But what does it mean to say sex is changed? Is Viagra a wonder drug? A magic bullet? The rejuvenating potion doctors sought for centuries? Supporters of the medicalization of sexuality certainly claim as much. Previous surveys suggested that when strictly defined as the inability to get an erection perhaps ten percent of men suffered at times from impotence. To appreciate the Viagra phenomenon we need to trace the emergence of the new pharmacological agents that arose in the 1990s but then situate them in the context of changing cultural attitudes toward masculinity, medicine, and the enhancement technologies.
